Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio Essence (BIOE) EBITDA Margin (2020 - 2025)

Bio Essence has reported EBITDA Margin over the past 6 years, most recently at 69.6% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 6698.0% year-over-year to 69.6%; the TTM value through Dec 2025 reached 47.43%, up 14359.0%, while the annual FY2025 figure was 47.43%, 18926.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 69.6% at Bio Essence, up from 10.42% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 95.31% in Q4 2023 and troughed at 924.3% in Q1 2025.
  • A 5-year average of 102.76% and a median of 64.0% in 2022 define the central range for EBITDA Margin.
  • On a YoY basis, EBITDA Margin climbed as much as 41939bps in 2025 and fell as far as -82562bps in 2025.
  • Year by year, EBITDA Margin stood at 93.3% in 2021, then soared by 59bps to 38.64% in 2022, then surged by 347bps to 95.31% in 2023, then plummeted by -97bps to 2.61% in 2024, then soared by 2566bps to 69.6% in 2025.
  • Business Quant data shows EBITDA Margin for BIOE at 69.6% in Q4 2025, 10.42% in Q3 2025, and 23.63% in Q2 2025.